Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 174

    1.

    Intraperitoneal cisplatin with systemic thiosulfate protection.

    Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M.

    Ann Intern Med. 1982 Dec;97(6):845-51.PMID: 6890785 [PubMed - indexed for MEDLINE]Related articles

    2.

    Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.

    Canal P, de Forni M, Chatelut E, Chevreau C, Johnson NP, Houin G, Bugat R.

    Acta Med Austriaca. 1989;16(3-4):84-6.PMID: 2609919 [PubMed - indexed for MEDLINE]Related articles

    3.

    Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection.

    Howell SB, Pfeifle CE, Wung WE, Olshen RA.

    Cancer Res. 1983 Mar;43(3):1426-31.PMID: 6681730 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    'Two-route chemotherapy' using cisplatin and its neutralizing agent, sodium thiosulfate, for intraperitoneal cancer.

    Abe R, Akiyoshi T, Baba T.

    Oncology. 1990;47(5):422-6.PMID: 2216298 [PubMed - indexed for MEDLINE]Related articles

    7.

    High-dose cisplatin with sodium thiosulfate protection.

    Pfeifle CE, Howell SB, Felthouse RD, Woliver TB, Andrews PA, Markman M, Murphy MP.

    J Clin Oncol. 1985 Feb;3(2):237-44.PMID: 4038510 [PubMed - indexed for MEDLINE]Related articles

    8.

    Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.

    Malmström H, Rasmussen S, Simonsen E.

    Gynecol Oncol. 1993 May;49(2):166-71.PMID: 8504983 [PubMed - indexed for MEDLINE]Related articles

    9.

    Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide.

    Zimm S, Cleary SM, Lucas WE, Weiss RJ, Markman M, Andrews PA, Schiefer MA, Kim S, Horton C, Howell SB.

    Cancer Res. 1987 Mar 15;47(6):1712-6.PMID: 3815369 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection.

    Markman M, Cleary S, Howell SB.

    Eur J Cancer Clin Oncol. 1985 Sep;21(9):1015-8.PMID: 4065175 [PubMed - indexed for MEDLINE]Related articles

    11.

    Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.

    Morgan RJ Jr, Newman EM, Doroshow JH, McGonigle K, Margolin K, Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B, Yen Y, Klevecz R.

    Cancer Res. 1998 Jul 1;58(13):2793-800.PMID: 9661893 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma.

    Markman M, Cleary S, Pfeifle C, Howell SB.

    Cancer. 1986 Jul 1;58(1):18-21.PMID: 3708543 [PubMed - indexed for MEDLINE]Related articles

    14.

    [Intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers]

    Kurihara N, Kumai K, Kubota T, Furukawa T, Yamamoto T, Shimada A, Shibata S, Saikawa Y, Ogawa S, Murayama Y, et al.

    Gan To Kagaku Ryoho. 1993 Aug;20(11):1645-8. Japanese. PMID: 8373238 [PubMed - indexed for MEDLINE]Related articles

    15.

    'Two-route chemotherapy' using intra-arterial cisplatin and intravenous sodium thiosulfate, its neutralizing agent, for hepatic malignancies.

    Abe R, Akiyoshi T, Koba F, Tsuji H, Baba T.

    Eur J Cancer Clin Oncol. 1988 Oct;24(10):1671-4.PMID: 2850191 [PubMed - indexed for MEDLINE]Related articles

    16.

    Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP).

    Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, Bartlett DL.

    Ann Surg Oncol. 1999 Sep;6(6):582-90.PMID: 10493628 [PubMed - indexed for MEDLINE]Related articles

    17.

    The administration of hypotonic intraperitoneal cisplatin during operation as a treatment for the peritoneal dissemination of gastric cancer.

    Tsujitani S, Fukuda K, Saito H, Kondo A, Ikeguchi M, Maeta M, Kaibara N.

    Surgery. 2002 Jan;131(1 Suppl):S98-104.PMID: 11821794 [PubMed - indexed for MEDLINE]Related articles

    18.

    A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.

    Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, Venzon DJ, Alexander HR.

    Cancer. 1998 Sep 15;83(6):1251-61. Erratum in: Cancer 1998 Nov 15;83(10):2241. PMID: 9740093 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.
    20.

    Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.

    Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr.

    Cancer Treat Rep. 1983 Mar;67(3):235-8.PMID: 6682012 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data